Steady Demand for Effective Treatment for Acute Lung Injury Prevails
One of the leading causes of morbidity, and mortality in critically ill patients, acute lung injury has a high incidence rate worldwide. As the mortality rate associated with the condition has been on a higher side, an effective treatment also continues to be in demand. Global acute lung injury market though remains on a steady uptrend is likely to be experiencing a dynamic landscape majorly on the research forefront. Significant players competing in acute lung injury treatment market are expected to invest their core research strength in novel therapies, and treatments that effectively enhance the outcome and thereby improve the quality of life of patients to a measurable extent. The therapeutic complications and associated high costs will however limit long-term market growth. Inadequate adoption of diagnosis aids like portable spirometers, and digital radiography machines is also expected to challenge rapid growth of acute lung injury treatment market.
Global Burden of Lung-related Diseases Continues to Pile up
The worldwide expanding elderly patient population, and notably growing awareness about health diagnostics are expected to give acute lung injury treatment market a collective push. Advent of technology that has been aiding in the exploration of new potential treatment methods for acute lung injury treatment will also bode well for market. Above all these factors, rising prevalence of lung-related disease conditions will predominantly drive the growth of acute lung injury treatment market. The Global Burden of Disease Study affirms the remarkably surging prevalence of lung-related conditions. Asthma stands among the most common chronic diseases in children, and adolescents, reportedly affecting over 14% of children globally. Chronic obstructive pulmonary disease (COPD) had more than 250 million recorded cases worldwide in 2016 and accounts for around 3 million deaths each year. Pneumonia also remains one of the leading causes of death of millions every year, including children under five years old. Besides, there are some other factors as well that may be responsible for acute lung injury, which include accidents, hypoxia, sepsis, excessive smoking, accidental inhalation of noxious fumes, and major trauma.
Preference for Mechanical Ventilation Intact, Clinical Trials of More Effective Treatment Alternatives in Pipeline
Mechanical ventilation remains the most preferred supportive method of acute lung injury treatment as it allows sufficient and frequent air/oxygen supply at tidal volumes, and boosts progress in oxygenation. Tracheotomy process is often recommended for those patients who require lengthy mechanical ventilation. Extracorporeal membrane oxygenation (ECMO) will continue to be sought-after for a limited number of cases. As far as the introduction of newer treatment alternatives is concerned, several clinical trials have been in progress, among which the FP-1201-lyo treatment for acute lung injury is currently in phase III of its clinical trials and expects the European marketing authorisation soon. Faron Pharmaceuticals, Ltd. is also involved in the development of multiple pharmacological treatments for acute lung injury, wherein the role of a consortium that comprises the European Commission, and Traumakine programme (University of Torino, University of Turku, and University College London Hospital) will be crucial. A couple of years ago, Windtree Therapeutics had published the results of its lung deposition study of aerosolised Lucinactant. As acute lung injury patients frequently suffer from augmented vascular leakage, reduced leakage is likely to remain the key objective of all therapies, and treatments.
Acute Lung Injury Remains an Unmet Medical Need
Although there had been a lot of developments in terms of the overall disease understanding, epidemiology, and pathophysiology, the fact repeatedly highlights a degraded quality of life of patients that lasts the lifetime. The rate of morbidity, and mortality also needs to be reduced to a large extent. On one side, acute lung injury treatment market exhibits a stable growth curve based on sustained demand but on the other hand, greater disease prevalence and ineffectiveness of the available treatments continue to hamper it as an unmet medical condition. Global acute lung injury treatment market thus anticipates some truly novel therapeutic procedures that would come with improved clinical outcomes. R&D in acute lung injury treatment market space is growing dynamically over the recent past and more focus on research will benefit the progress of acute lung injury treatment market in long run. Research has identified some of the biological markers associated with unsuccessful clinical outcomes. Researchers have also reported novel outcomes in the areas of lung-protective ventilation strategies, and fluid conservation, in form of improved patient survival rates. Moreover, a lot of interest has been developing around the potentially effective therapies like nutritional strategies, and statin therapy.
Pricing Remains a Deterrent Facing Developing, and Emerging Markets
Regional analysis of global acute lung injury market reveals that the US will continue to be dominant on account of the highest prevalence of the disease. Europe is also an important market given the disease prevalence, and the offerings of sophisticated European healthcare industry. On the flipside, the expensive price point associated with acute lung injury treatment continues to make it an unaffordable medical need across a majority of developing, and emerging nations.
Key Companies in Global Acute Lung Injury Treatment Market
Bayer AG, Glaxosmithkline Plc, Teva Pharmaceutical Industries Ltd., APEPTICO Forschung und Entwicklung GmbH, Medtronic Plc., Bachem Holding AG, Pfizer Inc., General Electric Company, Ony Biotech Inc, Koninklijke Philips N.V., Linde Plc., Altor BioScience Corporation, Carolus Therapeutics, Inc., Discovery Laboratories, Inc., and Faron Pharmaceuticals Ltd. are some of the major vendors driving competition in global acute lung injury treatment market landscape. The vendor landscape is remarkably competitive and is likely to be driven by the growing focus on R&D.
The Acute Lung Injury Treatment Market Has Been Segmented As Below:
By Injury Type
By End User
Key Elements Included In The Study: Global Acute Lung Injury Treatment Market
Post Sale Support, Research Updates & Offerings
We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.
Under uncertainty, traditional approaches to strategic planning can be downright dangerous. True ambiguity is no basis to forecast the future – degree of risk, the magnitude of circumstances, conditions and consequences are not known or unpredictable. To avoid dangerous binary views of uncertainty; strategic posture, moves and actions through market research is the best bet.Read more